California Public Employees Retirement System Trims Stock Position in Enovis Co. (NYSE:ENOV)

California Public Employees Retirement System decreased its stake in Enovis Co. (NYSE:ENOV – Get Rating) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 103,405 shares of the company’s stock after selling 478 shares during the quarter. California Public Employees Retirement System owned approximately 0.19% of Enovis worth $5,534,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Enovis by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,482,428 shares of the company’s stock worth $206,505,000 after acquiring an additional 43,799 shares in the last quarter. BlackRock Inc. grew its holdings in Enovis by 0.4% in the third quarter. BlackRock Inc. now owns 4,279,254 shares of the company’s stock valued at $197,144,000 after purchasing an additional 15,108 shares during the period. Diamond Hill Capital Management Inc. increased its position in shares of Enovis by 12.0% in the third quarter. Diamond Hill Capital Management Inc. now owns 2,317,552 shares of the company’s stock valued at $106,770,000 after buying an additional 247,922 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Enovis by 11.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,312,084 shares of the company’s stock worth $106,520,000 after buying an additional 234,649 shares during the period. Finally, Cooke & Bieler LP lifted its position in shares of Enovis by 4.3% during the 4th quarter. Cooke & Bieler LP now owns 1,612,114 shares of the company’s stock valued at $86,280,000 after buying an additional 66,350 shares in the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Enovis news, CEO Matthew L. Trerotola sold 18,917 shares of the business’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $56.21, for a total value of $1,063,324.57. Following the transaction, the chief executive officer now directly owns 175,910 shares in the company, valued at approximately $9,887,901.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Enovis news, COO Brady Shirley sold 1,490 shares of the company’s stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total value of $92,543.90. Following the transaction, the chief operating officer now owns 47,965 shares of the company’s stock, valued at $2,979,106.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew L. Trerotola sold 18,917 shares of Enovis stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $56.21, for a total transaction of $1,063,324.57. Following the sale, the chief executive officer now owns 175,910 shares of the company’s stock, valued at $9,887,901.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,881 shares of company stock worth $3,738,005. Insiders own 5.10% of the company’s stock.

Enovis Trading Down 1.3 %

Shares of Enovis stock opened at $55.08 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.38 and a quick ratio of 1.13. The stock’s 50 day simple moving average is $54.74 and its 200-day simple moving average is $56.17. The stock has a market cap of $3.00 billion, a P/E ratio of -57.38 and a beta of 2.01. Enovis Co. has a 1-year low of $43.88 and a 1-year high of $68.15.

Enovis (NYSE:ENOV – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Enovis had a positive return on equity of 3.70% and a negative net margin of 3.24%. The company had revenue of $406.20 million for the quarter, compared to analyst estimates of $389.95 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. Analysts predict that Enovis Co. will post 2.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ENOV. Canaccord Genuity Group reissued a “buy” rating and issued a $65.00 price target on shares of Enovis in a report on Tuesday, March 28th. Robert W. Baird upped their price target on shares of Enovis from $64.00 to $67.00 in a research report on Friday, May 5th. Finally, Wells Fargo & Company upgraded Enovis from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $55.00 to $67.00 in a report on Friday, May 12th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $64.88.

Enovis Company Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.